ALN-4324 + Placebo
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese or Overweight Healthy Volunteers
Conditions
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Mar 3, 2025 → Aug 31, 2027
NCT ID
NCT06845202About ALN-4324 + Placebo
ALN-4324 + Placebo is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for Obese or Overweight Healthy Volunteers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06845202. Target conditions include Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM).
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07465224 | Phase 2 | Recruiting |
| NCT06845202 | Phase 1/2 | Recruiting |
Competing Products
9 competing products in Obese or Overweight Healthy Volunteers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Bardoxolone methyl + Placebo | Kyowa Kirin | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| BMS-963272 + Placebo | Bristol Myers Squibb | Phase 1 | 32 |
| Aleniglipron + Placebo | Structure Therapeutics | Phase 2 | 47 |
| CRB-913 + Placebo | Corbus Pharmaceuticals | Phase 1 | 25 |